Ascletis, Inc.
1785 Jianghai Road,building No.1
Suite 804
Binjiang District
Hangzhou
China
Tel: +86-571-8538-9729
Website: http://ascletis.com.cn/
84 articles about Ascletis, Inc.
-
Ganovo (R) Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association
7/30/2018
The awarded paper won the highest scientific merits out of 577 conference papers submitted this year
-
More and more pharma companies follow the trend of planning initial public offerings on the Hong Kong Stock Exchange. Another trend following this path is the number of prominent investment bankers who have left their firms for biotech companies in the former British colony.
-
WuXi STA First CDMO to Support the Approval of an Innovative Drug in China Through the "MAH" Pilot
6/14/2018
WuXi STA enables Ascletis to receive NDA Approval from China FDA for Ganovo (R)
-
Ascletis Receives NDA Approval from China FDA for Ganovo
6/12/2018
Ascletis announced that China Food and Drug Administration (CFDA) has approved its Category 1 new drug, Ganovo (also known as Danoprevir or ASC08), for the treatment of viral hepatitis C.
-
Two Chinese Pharma Companies, WuXi AppTec and Ascletis Pharma, List IPOs on Asian Exchanges
5/8/2018
Shares of Chinese pharmaceutical and medical device company WuXi AppTec were a hot commodity Tuesday as the company made its debut on the Shanghai Stock Exchange. Another Chinese company, Ascletis Pharma, also chose a new stock listing. -
Ascletis Plans $100M C Round; Then Hong Kong IPO
1/22/2018
The company will use the money to fund clinical trials and develop a marketing operation.
-
Medivir Licenses Exclusive Rights To MIV-802 For Greater China To Ascletis
8/18/2017
-
Ascletis, Inc. Publishes Interim Data Of Phase II Study In Taiwan For Its Interferon-Free HCV Regimen
6/21/2016
-
Goldman, Sachs & Co. Invests US$20 Million In Ascletis, Inc.
12/2/2015
-
Ascletis, Inc. Scores $35 Million Financing
9/2/2015
-
Ascletis, Inc. Phase II Clinical Trial Of Its Interferon-Free HCV Regimen In Taiwan
8/31/2015
-
Ascletis, Inc. As The First Chinese Company To File Clinical Applications For Interferon-Free HCV Treatment
6/24/2015
-
Ascletis, Inc. Reports Strong Phase II Data For Hepatitis C Drug
3/18/2015
-
Ascletis, Inc. Gains China Market Rights From Janssen Research & Development to a Clinical Stage HIV Protease Inhibitor
4/30/2013
-
Week in Review: Ascletis, Inc. Collaborates With Roche on HCV Treatment
4/22/2013
-
Roche, Ascletis, Inc. to Collaborate on Hepatitis C Drugs for China
4/15/2013
-
ChinaBio(R) LLC Week in Review: Ascletis, Inc. In-Licenses China Rights to RNAi Cancer Drug
7/16/2012
-
Alnylam Pharmaceuticals, Ascletis, Inc. Create Strategic Collaboration to Develop ALN-VSP
7/12/2012
-
US-China Pharmaceutical Venture Ascletis, Inc. Receives Record-Level Research and Development Grant from Hangzhou
1/4/2012
-
Ascletis, Inc. Named for Financing Deal of the Year
12/1/2011